Invex Therapeutics Ltd. (AU:IXC) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Invex Therapeutics Ltd has announced the results of its Annual General Meeting, where several resolutions, including the adoption of the remuneration report and the election of directors, were carried, while the issuance of securities under an incentive plan was not approved. The company continues its focus on repurposing the drug Exenatide for neurological treatments, underlining its commitment to innovation in biopharmaceuticals.
For further insights into AU:IXC stock, check out TipRanks’ Stock Analysis page.